Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in China
Ascendis Pharma A/S - American Depositary Shares (ASND)
Last ascendis pharma a/s - american depositary shares earnings: 11/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ascendispharma.com
Company Research
Source: GlobeNewswire
- 50/50 joint venture with investor syndicate led by Vivo Capital – - Expands global reach for TransCon products – COPENHAGEN, Denmark, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced the formation of VISEN Pharmaceuticals (Visen), a joint venture with an investor syndicate led by Vivo Capital, to develop, manufacture and commercialize the company’s endocrinology rare disease therapies in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan. Details include: Ascendis has granted Visen exclusive rights to develop and commercialize TransCon hGH, TransCon PTH and TransCon CNP in Greater China, and has received 50 percent ownership of Visen.An investor syndicate led by Vivo, along with participation by Sofinnova Ventures, has invested $40 million and has received 50 percent ownership of Visen.Visen will
Show less
Read more
Impact Snapshot
Event Time:
ASND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASND alerts
High impacting Ascendis Pharma A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ASND
News
- United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic HypoparathyroidismGlobeNewswire
- Ascendis Pharma A/S (NASDAQ: ASND) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $116.00 price target on the stock.MarketBeat
- Ascendis Pharma A/S (NASDAQ: ASND) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $173.00 price target on the stock.MarketBeat
- Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr. [Yahoo! Finance]Yahoo! Finance
- Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.GlobeNewswire
ASND
Earnings
- 2/7/24 - Beat
ASND
Sec Filings
- 4/24/24 - Form 6-K
- 4/10/24 - Form 6-K
- 3/27/24 - Form 6-K
- ASND's page on the SEC website